Natixis Advisors LLC Takes Position in Haemonetics Co. (NYSE:HAE)

Natixis Advisors LLC acquired a new stake in Haemonetics Co. (NYSE:HAE - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,294 shares of the medical instruments supplier's stock, valued at approximately $1,194,000.

Several other hedge funds also recently added to or reduced their stakes in the business. Intech Investment Management LLC grew its holdings in shares of Haemonetics by 62.9% during the 3rd quarter. Intech Investment Management LLC now owns 22,329 shares of the medical instruments supplier's stock worth $1,795,000 after purchasing an additional 8,626 shares during the period. Cerity Partners LLC lifted its position in Haemonetics by 31.1% in the third quarter. Cerity Partners LLC now owns 8,855 shares of the medical instruments supplier's stock valued at $712,000 after buying an additional 2,102 shares during the last quarter. Loomis Sayles & Co. L P boosted its stake in Haemonetics by 8.1% during the third quarter. Loomis Sayles & Co. L P now owns 163,856 shares of the medical instruments supplier's stock worth $13,171,000 after buying an additional 12,310 shares during the period. FMR LLC increased its position in shares of Haemonetics by 206.3% during the third quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier's stock valued at $62,257,000 after acquiring an additional 521,640 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its stake in shares of Haemonetics by 174.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier's stock valued at $1,362,000 after acquiring an additional 10,774 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HAE. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an "overweight" rating and a $116.00 target price for the company. Raymond James reaffirmed a "strong-buy" rating and issued a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Bank of America lowered Haemonetics from a "neutral" rating to an "underperform" rating and decreased their target price for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. Barrington Research dropped their target price on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Finally, JMP Securities cut their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $101.22.

Haemonetics Stock Down 1.8 %

Shares of HAE stock traded down $1.18 during trading hours on Friday, reaching $63.03. 553,424 shares of the stock were exchanged, compared to its average volume of 666,316. Haemonetics Co. has a 12-month low of $58.80 and a 12-month high of $97.97. The business's fifty day moving average is $66.05 and its two-hundred day moving average is $74.68. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The firm has a market capitalization of $3.17 billion, a P/E ratio of 24.81, a P/E/G ratio of 1.11 and a beta of 0.43.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, research analysts expect that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.